Skip to content

Arcus Biosciences RCUS Contract Assets

Contract Assets at other companies

IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$6.56M
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$0-100%

Other financials

Income statement

See full
Revenue$17.0M-39.3%
Operating income-$134.0M-9.8%
Net income-$128.0M-14.3%
EPS (diluted)-$1.02+10.5%

Balance sheet

See full
Cash & equivalents$201.0M+4.7%
Total debt$113.0M+88.3%
Total equity$524.0M-1.3%
Total assets$997.0M-13.8%

Cash flow

See full
Operating cash flow-$138.0M-4.5%
CapEx--100%
Free cash flow-$138.0M-3.8%

Valuation

See full
Market cap$3.54B+226%
Enterprise value$3.46B+275%
P/S15×+7.3×

Profitability

See full
Operating margin-168.6%-52.7pp
Net margin-156.4%-47.5pp
FCF margin-207.2%

Returns & leverage

See full
Return on equity-70%+8.4pp
Debt / equity0.2×+0.1×
Current ratio-1.3×

Where this comes from

Reported directly by Arcus Biosciences in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerAssetNetCurrent.

The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcus Biosciences's contract assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arcus Biosciences's contract assets?
Arcus Biosciences (RCUS) reported contract assets of $3M in Q1 2026.
How has Arcus Biosciences's contract assets changed year-over-year?
Arcus Biosciences's contract assets decreased by 80.0% year-over-year, from $15M to $3M.
What is the long-term trend for Arcus Biosciences's contract assets?
Over 5 years (2020 to 2025), Arcus Biosciences's contract assets has grown at a 60.0% compound annual growth rate (CAGR), from $1.05M to $11M.
What does contract assets mean?
Revenue recognized under ASC 606 where the right to payment is conditional on something other than the passage of time — work performed but not yet billable.